Literature DB >> 19837264

Telomere aggregates in trisomy 21 amniocytes.

Efrat Hadi1, Reuven Sharony, Lilach Goldberg-Bittman, Tal Biron-Shental, Moshe Fejgin, Aliza Amiel.   

Abstract

Trisomy 21 is the most common chromosomal abnormality among persons with intellectual disability, with a live birth rate of 1 in 800-1,000. As such, this abnormality may serve as a model for human disorders that result from supernumerary copies of a genomic region. Down syndrome carries an increased risk of developing acute leukemia and other malignancies. Telomeres of tumor cells nuclei tend to form aggregates (TA). This study evaluated TA formation in amniocytes from trisomy 21 pregnancies, compared with amniocytes from normal euploid pregnancies. A commercially available peptide nucleic acid telomere kit was used to evaluate TA formation, using two-dimensional fluorescence microscopy. Significantly higher frequencies of TA were found in trisomy 21 amniocytes than in amniocytes from normal pregnancies. The TAs found in trisomy 21 amniocytes apparently represent an additional parameter that reflects the high genetic instability of this syndrome and its recognized predisposition to develop leukemia and other malignancies.

Entities:  

Mesh:

Year:  2009        PMID: 19837264     DOI: 10.1016/j.cancergencyto.2009.03.003

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

2.  Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome.

Authors:  Yasuo Kubota; Kumiko Uryu; Tatsuya Ito; Masafumi Seki; Tomoko Kawai; Tomoya Isobe; Tadayuki Kumagai; Tsutomu Toki; Kenichi Yoshida; Hiromichi Suzuki; Keisuke Kataoka; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Kentaro Ohki; Nobutaka Kiyokawa; Jiro Kagawa; Satoru Miyano; Akira Oka; Yasuhide Hayashi; Seishi Ogawa; Kiminori Terui; Atsushi Sato; Kenichiro Hata; Etsuro Ito; Junko Takita
Journal:  Cancer Sci       Date:  2019-09-10       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.